α52 isn't mobile-compatible yet. It's recommended to use a desktop or laptop.
α52
Alpha 52
Where AI meets Quant
MRNA
39.36
- 3.01%
Moderna, Inc.
Pharma & Biotech

News Sentiment

59m ago
Bullish 85%
Bearish 15%

News Summary

The company's stock surged significantly after providing an upbeat 2025 sales forecast and stronger cash outlook, alongside detailed 2026 guidance and multiple pipeline milestones. Preliminary full-year 2025 results were well-received by investors, sparking a major rally. Technical analysis indicates the stock is breaking out from a long-term bottom, with a Relative Strength Rating upgrade suggesting improving performance. The positive guidance update was a key topic among market analysts, contrasting with broader market declines.
Home Stock Model Insights
Support expand_more